Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by Benjamin Edwards Inc.

Benjamin Edwards Inc. grew its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 4,913.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,668 shares of the pharmaceutical company’s stock after acquiring an additional 6,535 shares during the period. Benjamin Edwards Inc.’s holdings in Vertex Pharmaceuticals were worth $3,101,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also modified their holdings of the company. Kestra Investment Management LLC grew its stake in shares of Vertex Pharmaceuticals by 28.7% during the third quarter. Kestra Investment Management LLC now owns 2,315 shares of the pharmaceutical company’s stock worth $1,077,000 after purchasing an additional 516 shares in the last quarter. B&L Asset Management LLC acquired a new position in shares of Vertex Pharmaceuticals during the third quarter worth $2,853,000. Erste Asset Management GmbH acquired a new position in shares of Vertex Pharmaceuticals during the third quarter worth $29,401,000. Captrust Financial Advisors grew its stake in shares of Vertex Pharmaceuticals by 2.2% during the third quarter. Captrust Financial Advisors now owns 14,409 shares of the pharmaceutical company’s stock worth $6,701,000 after purchasing an additional 307 shares in the last quarter. Finally, Atlantic Union Bankshares Corp grew its stake in shares of Vertex Pharmaceuticals by 4.6% during the third quarter. Atlantic Union Bankshares Corp now owns 7,558 shares of the pharmaceutical company’s stock worth $3,515,000 after purchasing an additional 329 shares in the last quarter. Institutional investors and hedge funds own 90.96% of the company’s stock.

Vertex Pharmaceuticals Trading Up 1.5 %

Shares of VRTX opened at $463.98 on Thursday. The company has a current ratio of 2.47, a quick ratio of 2.20 and a debt-to-equity ratio of 0.01. The firm’s 50-day moving average is $472.91 and its two-hundred day moving average is $475.25. Vertex Pharmaceuticals Incorporated has a twelve month low of $348.46 and a twelve month high of $519.88. The firm has a market capitalization of $119.49 billion, a P/E ratio of -233.16 and a beta of 0.36.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share for the quarter, topping the consensus estimate of $3.61 by $0.77. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The company had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.69 billion. During the same period in the prior year, the business posted $3.67 earnings per share. The firm’s revenue for the quarter was up 11.6% compared to the same quarter last year. On average, research analysts predict that Vertex Pharmaceuticals Incorporated will post -1.83 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on VRTX shares. UBS Group boosted their target price on shares of Vertex Pharmaceuticals from $562.00 to $586.00 and gave the stock a “buy” rating in a research note on Tuesday, November 5th. Oppenheimer reduced their price target on shares of Vertex Pharmaceuticals from $550.00 to $540.00 and set an “outperform” rating for the company in a research report on Wednesday, October 30th. StockNews.com cut shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 21st. Royal Bank of Canada boosted their price target on shares of Vertex Pharmaceuticals from $437.00 to $451.00 and gave the company a “sector perform” rating in a research report on Tuesday, November 5th. Finally, Morgan Stanley boosted their price target on shares of Vertex Pharmaceuticals from $473.00 to $476.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 5th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $504.38.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.